- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01482650
Comparison of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients
Comparison of the Effectiveness of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients
The investigators have performed a number of studies on novel airway devices, including an observational study on the performance of a new supraglottic airway named Baska mask. In this new proposed study the investigators would like to compare directly,in a randomized clinical trial, this device with the device the investigators routinely use - the single use laryngeal mask airway - LMA, in female patients undergoing general anaesthesia.
This study will determine which device performs best, as measured by key parameters (insertion success rate, seal pressures, time to and ease of insertion, failure rate, complications etc) as regarding the performance and safety profile of the Baska mask and the LMA.
The investigators have two study hypotheses, namely (1) non-inferiority of first placement attempt success rate of Baska vs LMA; and (2) greater seal pressure of the Baska mask vs LMA.
A number of secondary endpoints will be monitored and analyzed (time to and ease of insertion, failure rate, complications etc).
Study Overview
Status
Intervention / Treatment
Detailed Description
Airway management is essential component of the safe and efficient provision of general anaesthesia. Supraglottic airway devices have established place in the airway management.
The Baska mask is a new supraglottic airway device. It bears many of the features of the industry standard - the laryngeal mask airway (LMA), with few potential improvements:
- The cuff is not pressurized thus reducing the risk of oropharyngeal tissue damage.
- Improved cuff seal during the inspiratory phase of positive pressure ventilation which may reduce leak and make ventilation more efficient.
- An improved system for drainage of oropharyngeal contents intended to reduce the rate of lung aspiration.
- The Baska mask is inserted in neutral head position thus reducing the need for neck manipulation.
- There is integrated bite-block to reduce the risk of patients biting and blocking the airway.
The results from the observational study of the performance of the Baska mask are promising and the investigators feel a randomized comparative study against the gold standard device, the Laryngeal Mask Airway (LMA) is justified.
This study is a randomized, single blinded, controlled clinical trial. The participants will be allocated to two groups, in which the investigators will use either a single use LMA device or the Baska mask (single use).
Clinical Research Ethics Committee approval has been obtained. Suitable participants will be recruited after written informed consent and screened for inclusion and exclusion criteria.
Standard anaesthetic preassessment and anaesthesia will be provided.
Consenting patients will be randomly allocated to either of the 2 study groups.
Protocol for airway size selection and attempts at placement will be followed.
The investigators will monitor a number of parameters, including time and ease of insertion, airway seal pressure, airway leak, complications, haemodynamic and ventilatory parameters, ease of removal and other.
Follow up will be performed.
The investigators have two primary hypotheses:
- That the BASKA mask will have an insertion success rate that is no more than 20% less than that of the single use LMA device.
- That the seal pressure with the BASKA mask will be 40% higher than that of the single use LMA.
In addition to the above the investigators will evaluate a number of secondary outcomes.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Galway, Ireland
- Galway University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Written informed consent
- ASA 1-3
- No relevant allergies
- Body-mass index (BMI) 20-35
- Age 16-85
- Non-urgent surgery of planned duration 0.25-4 hrs
Exclusion Criteria:
- Inability of patient/parent to understand or consent for the trial
- Neck pathology
- Previous or anticipated problems with the upper airway or upper GI tract (reflux, hiatus hernia, oropharyngeal tumour, upper respiratory tract infection in the last 10 days)
- BMI >35
- Predicted or previously documented difficult airway
- Live Pregnancy
- Increased risk for Gastric Aspiration
- Current participation in another Clinical Study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Baska mask
|
The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
|
ACTIVE_COMPARATOR: single use laryngeal mask airway (LMA)
|
The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of successful placement of the supraglottic device on first attempt
Time Frame: Within 30minutes of commencement of general anaesthesia
|
The hypothesis is that the BASKA mask will have first placement attempt success rate that is no more than 20% less than that of the single use LMA device.
|
Within 30minutes of commencement of general anaesthesia
|
Seal pressure of the supraglottic device
Time Frame: Within 30minutes of commencement of general anaesthesia, immediately after successful placement is accomplished.
|
The investigators will measure the airway seal provided by the device used.
The hypothesis is that the seal pressure with the BASKA mask will be 40% higher than that of the single use LMA.
|
Within 30minutes of commencement of general anaesthesia, immediately after successful placement is accomplished.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall rate of successful placement of the supraglottic device
Time Frame: Within 30minutes of commencement of general anaesthesia. Up to 3 device placement attempts are allowed.
|
Within 30minutes of commencement of general anaesthesia. Up to 3 device placement attempts are allowed.
|
|
Number of device placement attempts
Time Frame: Within 30minutes of commencement of general anaesthesia
|
Within 30minutes of commencement of general anaesthesia
|
|
User - rated Ease of insertion of the device
Time Frame: Within 30minutes of commencement of general anaesthesia
|
the investigators will use 10cm visual analogue scale
|
Within 30minutes of commencement of general anaesthesia
|
vital parameters stability
Time Frame: In the period immediately before and during the first 35 minutes of the general anaesthesia
|
The investigators will record noninvasive arterial oxygen saturation, heart rate and blood pressure preoperatively, after anaesthesia is induced and after the airway is placed.
|
In the period immediately before and during the first 35 minutes of the general anaesthesia
|
Laryngeal view obtained on fiberoptic assessment
Time Frame: within 2hours of commencement of general anaesthesia
|
The investigators will perform this where feasible.
|
within 2hours of commencement of general anaesthesia
|
User rated Ease of removal of the device
Time Frame: At the time of device removal (usually within 15 minutes before or after the end of the general anaesthesia)
|
The investigators will use 10cm visual analogue scale
|
At the time of device removal (usually within 15 minutes before or after the end of the general anaesthesia)
|
Complication rates
Time Frame: from the moment general anaesthesia commenced up to 3 days postoperatively
|
Complications specifically monitored will be: blood staining, laryngospasm, lip damage, pain, dysphagia, dysphonia. The investigators will record other complications related to the use of the device, including but not limited to: desaturation episodes, loss of airway with need to manipulate mask/switch to alternative device, teeth damage, regurgitation, aspiration |
from the moment general anaesthesia commenced up to 3 days postoperatively
|
Duration of successful insertion attepts
Time Frame: Within 30 minutes of commencement of general anaesthesia
|
This outcome measure is defined as the period from the time device touched until successfull ventilation is achieved as per protocol.
|
Within 30 minutes of commencement of general anaesthesia
|
Collaborators and Investigators
Investigators
- Principal Investigator: John Laffey, FFARCSI, National University of Ireland, Galway, and Galway University Hospitals
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- C.A. 650
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Performance and Safety of an Airway Management Device
-
John LaffeyCompletedPerformance and Safety of an Airway Management DeviceIreland
-
John LaffeyCompletedPerformance and Safety of an Airway Management DeviceIreland
-
University College Hospital GalwayCompletedPerformance and Safety of a New Supraglottic Airway DeviceIreland
-
University of Colorado, DenverCompletedFunctionality and Performance of DeviceUnited States
-
Aretaieio HospitalRecruitingEndotracheal Intubation | Airway Management | Supraglottic Airway Device | Regional AnesthesiaGreece
-
ConvaTec Inc.CompletedSafety and Performance of Dressing Adhesive on Healthy VolunteersUnited Kingdom
-
University of ZurichUnknownTechnical and Non-technical Training of Airway Management on ICUSwitzerland
-
Schulthess KlinikMedical University InnsbruckCompletedAirway Morbidity | Device Induced Injury | Complication of Device Insertion | Necrosis, PressureSwitzerland, Austria
-
EndologixActive, not recruitingSafety and Performance of the Nellix Endovascular Sealing SystemGermany, Latvia, Luxembourg, Netherlands, New Zealand, Norway, Sweden, United Kingdom
-
Yale-NUS CollegeCompletedFocus of Study is Patient Responses to an Obesity Management Questionnaire Administered by SGH Life CentreSingapore
Clinical Trials on supraglottic airway placement and use
-
John LaffeyCompletedPerformance and Safety of an Airway Management DeviceIreland
-
Centre For International HealthKarolinska Institutet; University of Padova; Makerere University; Doctors with...Unknown
-
National Taiwan University HospitalUnknownBreast Neoplasms | Body Weight | Laryngeal MasksTaiwan
-
Seoul National University HospitalCompletedIntubation;DifficultKorea, Republic of
-
Seoul National University HospitalRecruitingFailed or Difficult IntubationKorea, Republic of
-
Maisonneuve-Rosemont HospitalCompletedAnesthesia Airway ManagementCanada
-
Lehigh Valley HospitalCompletedIntubation; DifficultUnited States
-
Jason SperryUnited States Department of DefenseRecruitingTrauma Injury | Airway ControlUnited States
-
Universiti Sains MalaysiaAmbu A/SCompletedGeneral AnaesthesiaMalaysia
-
National Taiwan University HospitalUnknownPrehospital Airway Management in Patients With Cardiac Arrest